Platinum Investment Management’s Five Prime Therapeutics, Inc. FPRX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2021
Q2 | – | Sell |
-182,993
| Closed | -$6.89M | – | 157 |
|
|
2021
Q1 | $6.89M | Sell |
182,993
-58,250
| -24% | -$1.45M | 0.15% | 46 |
|
|
2020
Q4 | $4.1M | Sell |
241,243
-86,171
| -26% | -$1.08M | 0.09% | 61 |
|
|
2020
Q3 | $1.54M | Hold |
327,414
| – | – | 0.04% | 90 |
|
|
2020
Q2 | $2M | Buy |
327,414
+76,198
| +30% | +$314K | 0.05% | 85 |
|
|
2020
Q1 | $570K | Hold |
251,216
| – | – | 0.01% | 108 |
|
|
2019
Q4 | $1.15M | Buy |
251,216
+59,979
| +31% | +$238K | 0.02% | 81 |
|
|
2019
Q3 | $741K | Hold |
191,237
| – | – | 0.02% | 89 |
|
|
2019
Q2 | $1.15M | Hold |
191,237
| – | – | 0.03% | 83 |
|
|
2019
Q1 | $2.56M | Hold |
191,237
| – | – | 0.06% | 54 |
|
|
2018
Q4 | $1.78M | Buy |
191,237
+69,661
| +57% | +$829K | 0.06% | 52 |
|
|
2018
Q3 | $1.69M | Buy |
121,576
+27,376
| +29% | +$407K | 0.05% | 59 |
|
|
2018
Q2 | $1.49M | Hold |
94,200
| – | – | 0.04% | 62 |
|
|
2018
Q1 | $1.62M | Buy |
94,200
+31,400
| +50% | +$613K | 0.05% | 56 |
|
|
2017
Q4 | $1.38M | Buy |
62,800
+42,000
| +202% | +$1.35M | 0.04% | 59 |
|
|
2017
Q3 | $850K | Buy |
+20,800
| New | +$653K | 0.02% | 68 |
|
Platinum Investment Management's FPRX Position: Q2 2021 in Review
Platinum Investment Management sold out of Five Prime Therapeutics, Inc. (FPRX) in Q2 2021, closing a stake of 182,993 shares — an estimated $6.89M sold.
Platinum Investment Management first reported a position in FPRX in Q3 2017 and held it in 15 quarters. The position peaked at $6.89M in Q1 2021. 0 funds tracked by Wall St. Rank hold FPRX as of Q2 2021.
- Platinum Investment Management reported no remaining Five Prime Therapeutics, Inc. position as of Q2 2021 after selling out during the quarter.
- Platinum Investment Management sold 182,993 Five Prime Therapeutics, Inc. shares in Q2 2021, an estimated $6.89M.
- Platinum Investment Management first reported a position in Five Prime Therapeutics, Inc. in Q3 2017 and held it in 15 quarters.
- Platinum Investment Management's Five Prime Therapeutics, Inc. position peaked at $6.89M in Q1 2021.
- 0 funds tracked by Wall St. Rank held Five Prime Therapeutics, Inc. as of Q2 2021.
Based on Platinum Investment Management's 13F filing for Q2 2021, filed 11 Aug 2021.